Conference Coverage

COORDINATEd effort boosts optimal therapy in patients with T2D and ASCVD


AT ACC 2023

– Twenty cardiology clinics successfully intensified the medical care they gave patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) after receiving a simple and scalable investigational intervention that gave the clinics’ staffs guidance on best prescribing practices and implementation and also provided quality-improvement feedback.

Within a year, these clinics quadrupled optimal medical management of these patients, compared with control clinics, in a randomized trial involving a total of 43 clinics and 1,049 patients.

“This multifaceted intervention is effective in increasing the prescription of evidence-based therapies in adults with T2D and ASCVD,” Neha J. Pagidipati, MD, said at the joint scientific sessions of the American College of Cardiology and the World Heart Federation.

Dr. Neha J. Pagidipati, cardiologist, Duke University, Durham, N.C. Mitchel L. Zoler/MDedge News

Dr. Neha J. Pagidipati

“The next step is to scale this intervention across cardiology practices” interested in improving the quality of care they deliver to these patients, added Dr. Pagidipati, a cardiologist specializing in cardiometabolic disease prevention at Duke University in Durham, N.C.

The goal is getting patients on triple therapy

The primary outcome of the COORDINATE-Diabetes trial was the change in the number of patients with T2D and ASCVD who received prescriptions for agents from three recommended medication classes and at recommended dosages: a high-intensity statin, a renin-angiotensin system inhibitor (RASi), and at least one agent from either of two classes that have both cardiovascular-protective and antihyperglycemic effects: the sodium-glucose cotransporter 2 (SGLT2) inhibitors, or the glucagonlike peptide 1 (GLP-1)–receptor agonists.

Among the 457 patients treated at the 20 cardiology clinics who received the quality-improvement intervention, 37.9% were on the promoted triple therapy after 12 months, compared with 14.5% of the 588 patients treated at the 23 clinics that continued with their usual care approach. This 23.4–percentage point increase in triple-class prescribing at recommended dosages represented a significant 4.4-fold increase in the goal prescribing endpoint after adjustment for possible confounders, Dr. Pagidipati reported.

Simultaneously with her report, the findings also appeared online in JAMA.

At baseline, 41%-50% of the patients were on both a high-intensity statin and a RASi, with a total of about 58%-67% on a high-intensity statin and about 70%-75% on a RASi. Fewer than 1% of patients were on SGLT2 inhibitors or GLP-1–receptor agonists at baseline. By design, no patient could be on all three categories of medication at baseline.

At their last follow-up visit (after 12 months for 97% of patients, or after 6 months for the remainder) 71% of the patients at practices that received the intervention were on a high-intensity statin, 81% were taking a RASi, and 60% were on an SGLT2 inhibitor or GLP-1–receptor agonist. Among the control patients, 58% were on a high-intensity statin, 68% on a RASi, and 36% were on one of the antihyperglycemic agents.

Effective interventions and the need for a champion

The clinics randomized to the active arm received instruction from a three-member team, either from an in-person or virtual one-time visit, on an intervention comprising several initiatives:

  • Analysis of the barriers to evidence-based care at each clinic.
  • Development of local interdisciplinary care pathways to address the identified barriers.
  • Facilitation of care coordination among clinicians – particularly among cardiology, endocrinology, and primary care clinicians.
  • Education of the clinic staff, including provision of educational materials.
  • Auditing of clinic performance using specified metrics and feedback on the findings.


Recommended Reading

How to get started with prescribing and advising on CGM
MDedge Cardiology
A purple warrior rises in the battle against diabetes
MDedge Cardiology
Therapy app cut A1c, drug intensification in T2D
MDedge Cardiology
Irregular sleep tied to markers of atherosclerosis
MDedge Cardiology
Toxic chemicals we consume without knowing it
MDedge Cardiology
Fewer than 10% of eligible type 2 diabetes patients get new, pricey drugs
MDedge Cardiology
Insomnia, short sleep linked to greater risk for MI
MDedge Cardiology
Old drug verapamil may have new use in type 1 diabetes
MDedge Cardiology
Lilly cuts insulin price by 70%, caps out-of-pocket cost
MDedge Cardiology
Biomarkers linked to elevated T2D MACE risk in DECLARE-TIMI 58
MDedge Cardiology